| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/10/2008 | US20080086119 System for perfusion management |
| 04/10/2008 | US20080086016 lisdexamfetamine, lisdexamfetamine dimesylate and lisdexamfetamine hydrochloride; attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity |
| 04/10/2008 | US20080086005 Novel crystalline forms of aripiprazole |
| 04/10/2008 | US20080086000 Prostaglandin reductase |
| 04/10/2008 | US20080085999 Modulation of gene expression using dna-rna hybrids |
| 04/10/2008 | US20080085995 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| 04/10/2008 | US20080085939 Use Of Sphingolipids For Prevention And Treatment Of Atherosclerosis |
| 04/10/2008 | US20080085938 Arylamino-Arylpropanolamine Derivatives and Methods of Their Use |
| 04/10/2008 | US20080085937 Made by reaction of 3-alkyloxazolidin-2,4-diones with either primary or secondary amines (or diamines); poly-N-(2-hydroxyalkanoyl)-N-alkylidene-N'-alkylidene-ureas which can be further polymerized with polyurethanes or polyureas with a larger degree of crystallinity; use in improved chromatographic resin |
| 04/10/2008 | US20080085936 Antiinflammatory agents, analgesics; 2-halo-4-hydroxy-5-methoxyphenyl-functional urea or thiourea compounds such as 1-(p-trifluoromethylbenzyl)-3-(2-iodo-4-hydroxy-5-methoxybenzyl)thiourea |
| 04/10/2008 | US20080085933 Comprising 55 to 98 wt % water, 0.1 to 10 wt % hydrophobic organic compound, and 2 to 50 wt % alkali metal or alkaline earth metal salt of a monoester of a saturated C6-C20 alcohol and a saturated dicarboxylic acid; excellent stability and outstanding clarity |
| 04/10/2008 | US20080085932 Pharmaceutical Compositions Useful In Prevention and Treatment of Beta-Amyloid Protein-Induced Disease |
| 04/10/2008 | US20080085931 Inhibiting cyclin D1 production in a cell by contacting the cell with an amount of arsenic trioxide effective to inhibit cyclin D1 production therein; treatment of mantle cell lymphoma |
| 04/10/2008 | US20080085930 Characterized by a powder X-ray diffraction pattern having one powder X-ray diffraction peak at about 10.0 degrees 2-theta; useful for treating and/or preventing central nervous system disorders such as epilepsy, stroke, muscle spasms, neuropathic pain, and migraine |
| 04/10/2008 | US20080085929 Inclusion compounds of fumagillol derivative or its salt, and pharmaceutical compositions comprising the same |
| 04/10/2008 | US20080085928 such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes |
| 04/10/2008 | US20080085927 Peroxisome proliferator activated receptors; dyslipidemia; anticholesterol agents; antidiabetic agents; cardiovascular disorders; gastrointestinal disorders; {4-[2-ethoxy-3-(4-trifluoromethyl-phenoxy)-propoxy]-2-methyl-phenoxy}-acetic acid |
| 04/10/2008 | US20080085926 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| 04/10/2008 | US20080085925 Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands |
| 04/10/2008 | US20080085923 Thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer; use with other drugs such as aspirin, clodipogrel, prasugrel, cangrelor, Fragmin; himbacine derivatives |
| 04/10/2008 | US20080085922 Ophthalmic device comprising a minimum effective amount of an anti-allergic agent wherein the administration system is a soft contact lens comprising etafilcon A and ketotifen, wherein system releases 10% to 75% of ketotifen in 60 minutes from administering to eye |
| 04/10/2008 | US20080085921 Emesis, dyspepsia, gastroparesis, constipation, gastroesophageal reflux, or post-operative ileus; cisapride analogs; side effect reduction of adverse events; (R)-quinuclidin-3-yl 6-((3S,4R)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl)hexanoate or salts |
| 04/10/2008 | US20080085920 Composition comprising N-butyl-1-deoxy-nojirimycin, D-glucaro-delta-lactam, and N-ethyl-1-dexynojirimycin in a pharmaceutically acceptable carrier; treatment of chronic pain and neurodegeneration, neuropathic pain, visceral pain, fibromyalgia pain, inflammatory pain, headache pain, muscle pain |
| 04/10/2008 | US20080085919 1H-Pyrazoles Useful In Therapy |
| 04/10/2008 | US20080085918 Fitness assay and associated methods |
| 04/10/2008 | US20080085917 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isoquinoline besylate salt, preparation and therapeutic use thereof |
| 04/10/2008 | US20080085916 Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators |
| 04/10/2008 | US20080085915 Emesis, dyspepsia, gastroparesis, constipation, gastroesophageal reflux, or post-operative ileus; stereoisomeric esterified cisapride analogs; side effect reduction of adverse events by avoiding the cytochrome P450 drug detoxification system |
| 04/10/2008 | US20080085914 Administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor, or a pharmaceutically acceptable salt thereof, for the prevention of, delay progression to overt to, or the treatment of diastolic dysfunction or diastolic heart failure |
| 04/10/2008 | US20080085913 Polymorphic Forms of a Gabaa Agonist |
| 04/10/2008 | US20080085912 5-(optionally substituted)-3-carboxy-isoxazoles such as 5-methylisoxazole-3-carboxylic acid; treating immune-mediated diseases, cancer, transplant rejection, psoriasis; Janus kinase inhibitors |
| 04/10/2008 | US20080085911 Utilization of HMG-CoA inhibitors and omega-3 fatty acids for reduction of Apo-B levels beyond those obtained with treatment of HMG-CoA inhibitor alone; especially useful for treatment of hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, vascular disease, atherosclerotic disease |
| 04/10/2008 | US20080085910 For inflammatory bowel disease; oral administration, bioavailability, pharmacokinetics; 2-(2,6-Dichlorobenzamido)-5-[4-(ethyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid methyl ester for example |
| 04/10/2008 | US20080085909 Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one |
| 04/10/2008 | US20080085908 A2b adenosine receptor antagonists |
| 04/10/2008 | US20080085907 Reverse transcriptase inhibitors; use against HIV with drug resistance to NNRTI's (Non Nucleoside Reverse Transcriptase Inhibitor drugs); Diaryl Pyrrolo(2,3-d)pyrimidines, diaryl purines, diaryl v-triazolo(4,5-d)pyrimidines |
| 04/10/2008 | US20080085906 Use raising HDL cholesterol; heart disease; or pyrazine-2-carboxamides; 5-(4-chloro-phenyl)-6-cyclopropylmethoxy-N-((1R,2R)-2-hydroxy-cyclohexyl)-nicotinamide for example |
| 04/10/2008 | US20080085905 Pyrazine-2-carboxamide derivatives |
| 04/10/2008 | US20080085904 Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant |
| 04/10/2008 | US20080085903 Novel crystalline forms of aripiprazole |
| 04/10/2008 | US20080085902 Prevention or treatment of proliferative diseases by administering a VEGF inhibitor compound such as 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and one or more chemotherapeutic agents such as N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; cancer |
| 04/10/2008 | US20080085901 Heteroaryl Substituted Quinolin-4-Ylamine Analogues |
| 04/10/2008 | US20080085900 Sulfonylguanidine compounds and pharmaceutical uses thereof |
| 04/10/2008 | US20080085899 Tetrahydrothiopyrano pyrazole cannabinoid modulators |
| 04/10/2008 | US20080085898 And 8-substituted 2-(imidazolo[4,5-c]pyridinyl)purines; Janus kinase 3 inhibitors; autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection |
| 04/10/2008 | US20080085897 Inhibitors of cyclic guanosine monophosphate-metabolizing phosphodiesterases (cGMP PDE); cardiac insufficiency, cancer, bladder disorders, or prostate hyperplasia; 2-[2-ethoxy-5-(4-methyl-piperazine-1-sulphonyl)-phenyl]-5,7-dimethyl-3H-imidazo-[5,1-f]-[1,2,4]triazin-4-one for example |
| 04/10/2008 | US20080085896 Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications |
| 04/10/2008 | US20080085895 Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds |
| 04/10/2008 | US20080085894 Alpha-(n-sulfonamido)acetamide derivatives as beta-amyloid inhibitors |
| 04/10/2008 | US20080085893 N-Hydroxy (2S)-2-hydroxy phenyl or heteroaryl sulfonamide derivatives; for example, N-Hydroxy (2S)-2-hydroxy-3-{N-[4-(4- chlorophenoxy)phenyl], N- methanesulfonylamino}propionamide; for treating disorders related to matrix metalloproteases, particularly useful for treating strokes; |
| 04/10/2008 | US20080085892 Liquid dosage form of acetaminophen |
| 04/10/2008 | US20080085891 Asthma and allergic inflammation modulators |
| 04/10/2008 | US20080085890 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof |
| 04/10/2008 | US20080085889 Amidomethyl-Substituted 1-(Carboxyalkyl) Cyclopentyl-Carbonylamino-Benzazepine-N-Acetic Acid Compounds, Process and Intermediate Products for Their Preparation and Pharmaceutical Compositions Containing Them |
| 04/10/2008 | US20080085888 Synergistic combination of antipsychotic agent and a second therapeutic agent, which is (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine, for treating psychiatric disorders, particularly, cognitive impairment disorders |
| 04/10/2008 | US20080085887 Hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy; e.g. (R)-3-(1-(3,4-difluorophenyl) propan-2-yl)-2-(3-hydroxypyridin-2-yl) 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one |
| 04/10/2008 | US20080085886 Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide |
| 04/10/2008 | US20080085885 Selective melanocortin-4 receptor agonist, dose dependently reducing ethanol self administration; alcoholism, alcohol abuse |
| 04/10/2008 | US20080085884 Eating disorders, psychological disorders, sexual disorders, nervous system disorders, sleep disorders, autism; 4-(Benzyloxy)-6'-[3-methyl-3-(methylamino)pyrrolidin-1-yl]-2H-1,3'-bipyridin-2-one for example |
| 04/10/2008 | US20080085883 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
| 04/10/2008 | US20080085882 Chemotherapeutic agent and an antitumor modulator of bis(3-amino-1-alkanolato-)-di- mu -[halo/hydroxyl/thiocyanato/nitro]-di-Copper complex |
| 04/10/2008 | US20080085881 Administering from two to six cycles of oxaliplatin; stopping the treatment during which the patient is maintained on 5-fluorouracil alone or in combination with leucovorin; reintroducing oxaliplatin treatment |
| 04/10/2008 | US20080085880 crystalline forms of zotarolimus (ABT-578); bioavailability, solubility |
| 04/10/2008 | US20080085879 Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation |
| 04/10/2008 | US20080085878 Superoxide dismutase-2 expression and modulation for glaucoma diagnosis and therapy |
| 04/10/2008 | US20080085877 Therapeutic methods of using estrogen compositions |
| 04/10/2008 | US20080085876 Insect sting treatment |
| 04/10/2008 | US20080085875 Crystalline forms of 11ss-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17a-pregna-4,9-dien-3-one |
| 04/10/2008 | US20080085874 Small molecule potentiator of hormonal therapy for breast cancer |
| 04/10/2008 | US20080085873 Disease treatment methods |
| 04/10/2008 | US20080085872 Administering colesevelam hydrochloride, and an antihyperlipidemic agent; a plasma HDL-raising agent; an antihypercholesterolemic agent; an acyl-coenzyme A: a cholesterol acyltransferase (ACAT) inhibitor; a cholesterol absorption inhibitor; a bile acid sequestrant anion exchange resin |
| 04/10/2008 | US20080085871 Polysaccharide component protects the 5-FU from absorption in the upper gastrointestinal tract, delivers the 5-FU to the colorectal area |
| 04/10/2008 | US20080085870 Isolated polynucleotides comprising a nucleic acid which operably encodes 50 contiguous amino acids, nucleic acids are fragments of a codon-optimized coding region; a carrier |
| 04/10/2008 | US20080085869 Sense strand, antisense strand having complementarity to both the sense strand and a target gene, forming a duplex, a conjugate, facilitating cellular delivery, and a linker molecule; facilitates delivery to a cell, tissue or organism |
| 04/10/2008 | US20080085868 Non-infectious nucleic acid construct encoding a recombinant antibody to that agent; injection of a nucleic acid construct, in the form of a plasmid, encoding a virus-neutralising single chain antibody fragment mediates in vivo expression of antibodies; protecting an animal against exposure to a virus |
| 04/10/2008 | US20080085867 Early detection and prognosis of colon cancers |
| 04/10/2008 | US20080085861 Gas1 polypeptides |
| 04/10/2008 | US20080085858 Pharmaceutical Composition |
| 04/10/2008 | US20080085855 or improving the integrity of body passageways following surgery, such as at a graft site, or injury. Delivery devices including one or more therapeutic agents and a mesh are described.microtubule stabilizing agents, anti-angiogenic factors, inhibitors of smooth muscle cell growth or proliferation, |
| 04/10/2008 | US20080085853 nuclear delivery construct comprises (i) protein H or a fragment or derivative thereof that is capable of being targeted to the nucleus of a eukaryotic cell; |
| 04/10/2008 | US20080085331 Glucose, sodium glycocholate, and carrier; non-aersol dispenser |
| 04/10/2008 | US20080085329 Use of oxygen antagonist in vivo such as DMSO, carbon monoxide, methylmercaptan, mercaptoethanol, thiocyanate, hydrogen cyanide, or carbon disulfide; organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer |
| 04/10/2008 | US20080085328 Substituted 4-aryl-chromene as activator of caspases and inducer of apoptosis and as antivascular agent and the use thereof |
| 04/10/2008 | US20080085325 Dialysis Solution, Formulated And Stored In Two Parts, Comprising Phosphate |
| 04/10/2008 | US20080085324 Compositions and methods for detecting and treating renal injury and inflammation |
| 04/10/2008 | US20080085322 Administering composition of beeswax and fatty acid-containing oil, and sterol; nutraceuticals; enhanced proliferation of hematopoietic cells and immune functions of the body |
| 04/10/2008 | US20080085320 Treating cognitive and mental conditions in adults such as attention deficit hyperactivity disorder using a polyunsaturated fatty acid (PUFA) esterified to a phosphatidylserine backbone and having improved bioavailability; no fishy smell |
| 04/10/2008 | US20080085319 Lipids containing omega-3 and omega-6 fatty acids |
| 04/10/2008 | US20080085318 Coated compositions and methods for preparing same |
| 04/10/2008 | US20080085317 Method and Formulation for Treating Resistance to Antihypertensives and Related Conditions |
| 04/10/2008 | US20080085315 Amorphous ezetimibe and the production thereof |
| 04/10/2008 | US20080085314 Comprises controlled release acetaminophen, non-steroidal anti-inflammatory drug, and agent capable of reducing gastric acid secretion |
| 04/10/2008 | US20080085313 Administering an endothelin antagonist such as sitaxsentan; freeze drying |
| 04/10/2008 | US20080085312 Multi-Phase Release Potassium Guaiacolsulfonate Compositions |
| 04/10/2008 | US20080085311 Antihistamine-decongestant combinations |
| 04/10/2008 | US20080085310 Capecitabine rapidly disintegrating tablets |
| 04/10/2008 | US20080085308 Granules Comprising Paracetamol, a Nsaid and a Sugar Alchohol Made by Melt Extrusion |
| 04/10/2008 | US20080085306 Topiramate compositions and methods of enhancing its bioavailability |
| 04/10/2008 | US20080085303 Administering 5-80 mg of a single dose with 200-300 ml of 4-40% ethanol to provide a secondary peak of blood drug concentration about 12 hours later along with providing pain relief; solid dosage containing hydrophilic gum particles of #270 mesh size; alcoholic beverage-resistant; no dose dumping |
| 04/10/2008 | US20080085302 Administering a time-dependent antimicrobial drug transdermally to achieve a serum concentration that remains above the minimum inhibitory concentration (MIC) of the drug consistantly to reduce risk of drug resistance and gastrointstinal side effects; zero order kinetics; shortened therapy duration |